Key Takeaways:
- Regeneron paid $37M to add two targets and option six more in its CytomX deal
- Total potential value of the expanded pact reaches about $4 billion
- The expansion comes as Astellas, BMS, Moderna and Amgen all exited CytomX partnerships
Back
Regeneron expands CytomX cancer deal to $4B as partners exit
Regeneron doubled down on CytomX's prodrug technology with a $4 billion deal expansion, even as three other partners walked away from the platform.
Regeneron Pharmaceuticals paid $37 million to add two cancer targets to its CytomX Therapeutics collaboration and secured options on six more, swelling the deal's potential value to about $4 billion.
"This expanded collaboration reflects our conviction in the conditional bispecific approach to treat tumors more selectively," a Regeneron spokesperson said.
The expansion roughly doubles the $2 billion ceiling of the original 2022 pact, which paid CytomX $30 million upfront. Regeneron now has the option to nominate up to six additional targets beyond the two added this week, with milestone payments tied to each.
The vote of confidence arrives as CytomX's other big-name partners retreat. Astellas terminated its agreement in the first quarter, Bristol Myers Squibb followed in May, Moderna paused its collaboration, and Amgen walked away from licensed programs — leaving Regeneron as the biotech's most important backer.
Why Regeneron Stayed
CytomX's Probody platform keeps biologic drugs inactive until they reach the tumor microenvironment, reducing on-target, off-tumor toxicity that limits many cancer therapies. Regeneron is applying the technology to its bispecific antibody platform, aiming to create conditionally active molecules that spare healthy tissue. The approach targets a fundamental limitation in oncology: widening the therapeutic window without sacrificing efficacy.
Bristol Myers Squibb tested the same premise with a masked successor to Yervoy but scrapped the program after a Phase 1/2 trial. That failure, along with the partner exits, raised questions about whether the technology can deliver on its promise. CytomX has yet to produce pivotal-stage data validating the platform in humans.
Cash Runway Buys Time for Data
CytomX holds $346.7 million in cash, enough to fund operations into the second half of 2028, according to its most recent filing. The biotech is advancing two clinical candidates, including varsetatug masetecan, or Varseta-M, a masked antibody-drug conjugate for colorectal cancer that could enter a registrational trial. Phase 1 data on its second clinical program are also expected within that window.
For Regeneron, the expanded deal provides access to a pipeline of conditionally active bispecifics at a relatively low upfront cost. The $37 million payment is modest for a company with $14 billion in annual revenue, and the milestone-heavy structure means Regeneron only pays for programs that reach development and commercial targets. CytomX shares, which have fallen as partners exited, could see renewed interest if the Regeneron-backed programs generate clinical data.
This article is for informational purposes only and does not constitute investment advice.
[1] REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics[2] Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact - Fierce Biotech[3] Regeneron and CytomX extend cancer therapy partnership to $4bn deal[4] Lilly enters $1.9B kidney disease deal for Ascidian’s exon editors[5] With billions of dollars at stake, trio of Bay Area biotechs nail down deals
